Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2191.90 | 3,639 Cr | 31.60 | 6.01 | 1.09 | 19.03 | 24.66 | 14.52 | ||
380.85 | 3,557 Cr | 34.88 | 4.53 | 0.11 | 12.98 | 12.14 | 6.46 | ||
350.00 | 3,550 Cr | 55.29 | 5.34 | 0.03 | 9.66 | 11.45 | 4.78 | ||
367.10 | 3,359 Cr | 17.23 | 2.17 | 0.54 | 12.58 | 11.51 | 6.92 | ||
1329.30 | 3,282 Cr | 35.22 | 4.01 | 0.00 | 11.39 | 15.94 | 9.52 | ||
461.70 | 3,251 Cr | 12.86 | 1.20 | 0.00 | 2.88 | 3.79 | 6.77 | ||
527.00 | 3,219 Cr | -599.50 | 3.86 | 0.00 | -2.93 | -2.42 | -0.57 | ||
| Median: 7 Co. | — | 461.70 | 3,359 Cr | 31.60 | 4.01 | 0.03 | 11.39 | 11.51 | 6.77 |
Novartis India Ltd (NOVARTIND) is currently trading at 1,303.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products. Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today. The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues. NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions. The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Over the past 52 weeks, Novartis India Ltd has traded between a low of ₹750.00 and a high of ₹1,588.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Novartis India Ltd has a market capitalization of approximately 3,282.15. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Novartis India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,282.15 Cr, Novartis India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Novartis India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Novartis India Ltd is 35.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The sale is part of Novartis AG's global strategy to transform into a pure-play innovative medicines company and follows a strategic review of its assets.
Novartis AG is selling its stake as part of a global strategy to transform into a 'pure-play innovative medicines company,' focusing on patented therapies and streamlining its worldwide operations.
Novartis AG is selling its 70.68% stake as part of a global strategic review to transform into a 'pure-play innovative medicines company' and focus on its core R&D and new drug portfolio.
Novartis AG is selling its stake as part of a global strategic review to transform into a 'pure-play innovative medicines company' and streamline its worldwide operations.
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products.
Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today.
The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues.
NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions.
The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,282 Cr
Low Risk
35.2
34.1
1.9
4.0
1,588.40
750.00
Sales CAGR
Profit CAGR
ROE
ROCE
Open Offer Update
Axis Capital (Manager) informed BSE that NIL (0) equity shares — NIL% of the 64,19,608-share open offer for Novartis India — were tendered on June 12, 2026 (demat and physical); tenders subject to validation per Letter of Offer.
Open Offer Tender Update
Axis Capital disclosed that zero equity shares were tendered (demat or physical) in the open offer for 64,19,608 shares (26% of voting capital) of Novartis India as of June 12, 2026; tenders subject to validation.
Open Offer Update
Open offer for 64,19,608 shares (26%) of Novartis India: Manager reports NIL equity shares tendered in both demat escrow and physical form on June 11, 2026; valid acceptances subject to verification per Letter of Offer/SEBI SAST.
Open Offer Update
Manager reports that 0 of 64,19,608 equity shares (26% of voting capital) were tendered on June 11, 2026 in both demat and physical form for the open offer for Novartis India.
Open Offer
Acquirers WaveRise, ChrysCapital Fund X and Two Infinity Partners (with PACs) launched an open offer to acquire 64,19,608 shares (26% of voting capital) of Novartis India at INR 860.64/share; tendering period 11–24 Jun 2026; Axis Capital is manager.
Open Offer Notice
Novartis India notified BSE that it published the Committee of Independent Directors' reasoned recommendations on the open offer by WaveRise, ChrysCapital and Two Infinity Partners (with PACs), via newspaper ads on June 6, 2026.
Bearish
4
Neutral
3
Bullish
7
Bearish
19
Neutral
3
Bullish
24
Bearish
15
Neutral
0
Bullish
17
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
